Articles tagged "Calcineurin"

2019 American Transplant Congress
Natural Course Of Tacrolimus Intra-patient Variability In Liver Transplant Recipients
N. Wilson, S. Tremblay, N. S. Ejaz, K. Zheng, J. Garrett, S. A. Shah, R. R. Alloway, T. E. Kaiser
University of Cincinnati, Cincinnati, OH
*Purpose: The evolution of tacrolimus (TAC) intra-patient variability (IPV) post liver transplant (LT) remains to be characterized. Identification of factors associated with high TAC-IPV may…
2019 American Transplant Congress
Transcriptome Profiling Of Renal Transplant Biopsies With Acute Cellular Rejection From Patients On Calcineurin Inhibitor-based Or Cni-avoidance Immunosuppression
D. Dobi¹, F. Vincenti², Z. G. Laszik¹
¹Department of Pathology, University of California, San Francisco, San Francisco, CA, ²Departments of Medicine and Surgery, University of California, San Francisco, San Francisco, CA
*Purpose: Despite their suboptimal toxicity profile, calcineurin-inhibitors (CNIs) remain the cornerstone of renal transplant immunosuppression. Previous efforts to completely eliminate CNIs failed, because CNI-avoidance protocols…
2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
J. Kim¹, H. Cho², J. Park³, M. Kwak⁴, B. Kim⁴, J. Lee⁵, D. Kim¹, B. Kim⁶, Y. Kim¹, H. Lee¹
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Chungbuk National University Hospital, Cheongju, Korea, Republic of, ³Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴Chunlab Inc., Seoul, Korea, Republic of, ⁵Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Hallym University, Chuncheon, Korea, Republic of
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…
2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…
2019 American Transplant Congress
Prevalence of Non-Adherence to Immunosuppressive Medications in Kidney Transplant Recipients, Barriers and Predictors
S. Taj¹, H. Baghaffar², D. Alnajjar², N. Almashabi³, S. Ismail⁴
¹King Saud Bin Abdulaziz University For Health Sciences, Jeddah, Saudi Arabia, ²Ibn Sina College, Jeddah, Saudi Arabia, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Pharmaceutical Care Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
*Purpose: Non-adherence to immunosuppressant therapy (IST) is one of the major factors leading to graft rejection. To our knowledge, limited data exist on the prevalence…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…
2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
T. Jouve¹, J. Noble¹, X. Fonrose², B. Janbon¹, G. Fiard³, P. Malvezzi¹, L. Rostaing¹
¹Nephrology, Dialysis, Aphereses and Transplantation Department, Grenoble University Hospital, Grenoble, France, ²Pharmacology, Pharmacogenetics and Toxicology Laboratory, Grenoble University Hospital, Grenoble, France, ³Urology and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…
2019 American Transplant Congress
Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients
K. D. Belfield¹, D. Malhotra², M. Waleed³, E. A. Cohen¹
¹Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³University of Connecticut School of Pharmacy, Storrs, CT
*Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) has become an attractive alternative to tacrolimus immediate release (TacIR) due to its once daily dosing scheme, favorable…
2019 American Transplant Congress
Belatacept Conversion for Calcineurin Inhibitor-Associated Thrombotic Microangiopathy in Kidney Transplant Recipients
S. A. Muhsin, K. Safa, H. M. Gilligan, E. C. Heher, W. W. Williams, D. M. Wojciechowski
Nephrology Division, MGH, Boston, MA
*Purpose: Thrombotic Microangiopathy (TMA) in kidney transplant recipients is a serious complication that can cause graft loss. It can be associated with immunosuppressive medications such…
2019 American Transplant Congress
Calcineurin Inhibitor Holiday for Management of Post Transplant Acute Kidney Injury
S. Sriperumbuduri, D. Lazarus, T. Fairhead, S. Hoar, J. Karpinski, G. Knoll
Nephrology, The Ottawa hospital, Ottawa, ON, Canada
*Purpose: Calcineurin inhibitors (CNI), despite dominating the armamentarium of post transplant medications, are associated with long term nephrotoxicity and also delayed recovery of renal function…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »